Linda Avey is a founding Managing Partner of Humain Ventures, investing at the intersection of AI and life sciences.. She was at the forefront of the digital health movement as a founder of 23andMe and the first independent board director of Rock Health. Her interests span precision health, AI-driven drug development, and the emergence of biology as a novel operating system. Linda is on the board of fellows of Stanford Medical School and is a current or former advisor to health and science companies including Colossal Biosciences (driving deextinction), Verily (Alphabet’s life science subsidiary), and Ôura (a leading health tracking wearable). She is also a director at the Human Immunome Project and an advisor to London-based Giant Ventures.